High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

NCT01840566 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Carmustine
DRUG: Etoposide
DRUG: Cytarabine
DRUG: Melphalan
BIOLOGICAL: Pegfilgrastim
BIOLOGICAL: 19-28z T CELLS
PROCEDURE: Autologous Stem Cell Transplantation

Sponsor

Memorial Sloan Kettering Cancer Center